CA2685599A1 - Composes pour traiter la dystrophie musculaire de duchenne - Google Patents
Composes pour traiter la dystrophie musculaire de duchenne Download PDFInfo
- Publication number
- CA2685599A1 CA2685599A1 CA002685599A CA2685599A CA2685599A1 CA 2685599 A1 CA2685599 A1 CA 2685599A1 CA 002685599 A CA002685599 A CA 002685599A CA 2685599 A CA2685599 A CA 2685599A CA 2685599 A1 CA2685599 A1 CA 2685599A1
- Authority
- CA
- Canada
- Prior art keywords
- thiazole
- imidazo
- alkyl
- nr4c
- methylimidazo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Diabetes (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention porte sur des composés représentés par la formule générale (I) dans laquelle X1, X2, X3, R1, R2, R3, Y et Z sont tels que définis dans le descriptif. Lesdits composés s'utilisent pour le traitement et la prévention de la dystrophie musculaire de Duchenne, de la dystrophie musculaire de Becker et de la cachexie.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0714303.5 | 2007-07-23 | ||
GB0714303A GB0714303D0 (en) | 2007-07-23 | 2007-07-23 | Use of compounds for preparing anti-tuberculosis agents |
GB0803906A GB0803906D0 (en) | 2008-03-03 | 2008-03-03 | Compounds for treating duchenne muscular dystrophy |
GB0803906.7 | 2008-03-03 | ||
PCT/GB2008/002495 WO2009013477A1 (fr) | 2007-07-23 | 2008-07-21 | Composés pour traiter la dystrophie musculaire de duchenne |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2685599A1 true CA2685599A1 (fr) | 2009-01-29 |
Family
ID=39884469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002685599A Abandoned CA2685599A1 (fr) | 2007-07-23 | 2008-07-21 | Composes pour traiter la dystrophie musculaire de duchenne |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP2167508A1 (fr) |
JP (1) | JP2010534231A (fr) |
AU (1) | AU2008278824A1 (fr) |
CA (1) | CA2685599A1 (fr) |
WO (1) | WO2009013477A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201412010D0 (en) | 2014-07-04 | 2014-08-20 | Summit Corp Plc | Treatment of hypertransaminasemia |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3549936T1 (sl) * | 2003-04-11 | 2021-09-30 | Ptc Therapeutics, Inc. | Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni |
WO2007019345A1 (fr) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Dérivés de l’imidazopyridine en tant qu’agents modulant la sirtuine |
-
2008
- 2008-07-21 AU AU2008278824A patent/AU2008278824A1/en not_active Abandoned
- 2008-07-21 JP JP2010517478A patent/JP2010534231A/ja active Pending
- 2008-07-21 WO PCT/GB2008/002495 patent/WO2009013477A1/fr active Application Filing
- 2008-07-21 EP EP08776016A patent/EP2167508A1/fr not_active Withdrawn
- 2008-07-21 CA CA002685599A patent/CA2685599A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2010534231A (ja) | 2010-11-04 |
WO2009013477A1 (fr) | 2009-01-29 |
AU2008278824A1 (en) | 2009-01-29 |
EP2167508A1 (fr) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101472248B1 (ko) | 뒤시엔느 근이영양증의 치료 | |
WO2008029152A2 (fr) | Traitement de la dystrophie musculaire de duchenne | |
AU2013358591B2 (en) | Pyrimido [4,5-b]quinoline-4,5 (3H,10H)-diones as nonsense mutation suppressors | |
US20120149741A1 (en) | Treatment of duchenne muscular dystrophy | |
EP3148539B1 (fr) | Inhibiteurs d'histone désacétylase, et compositions et méthodes d'utilisation de ceux-ci | |
KR20090005296A (ko) | 뒤시엔느 근이영양증의 치료 | |
WO2014159214A1 (fr) | Inhibiteurs d'histone désacétylase, et compositions et méthodes d'utilisation de ceux-ci | |
AU2018200421A1 (en) | Naphthyridinedione derivatives | |
CA2955059A1 (fr) | Derives de spiroquinoxaline en tant qu'inhibiteurs de la mort cellulaire regulee non apoptotique | |
CN110914253B (zh) | 一类异吲哚酮-酰亚胺环-1,3-二酮-2-烯化合物、其组合物和用途 | |
JP2019509272A (ja) | 脊髄性筋萎縮症の治療のための併用療法 | |
JP7110325B2 (ja) | インドールアミン 2,3-ジオキシゲナーゼ及び/又はトリプトファン 2,3-ジオキシゲナーゼの阻害剤 | |
CA3087807A1 (fr) | Inhibteurs de l'indoleamine 2,3-dioxygenase et/ou du tryptophane dioxygenase | |
EP3152208B1 (fr) | Pyrimido [4,5-b]quinoline-4,5(3h, 10h)-diones comme suppresseur de mutations non-sens | |
CA2685599A1 (fr) | Composes pour traiter la dystrophie musculaire de duchenne | |
JP2017516829A (ja) | ピリドピリミジンジオン誘導体 | |
JP2024072283A (ja) | Ahrアゴニスト |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20120723 |